{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T20:31:29Z","timestamp":1790281889895,"version":"4.1.0"},"reference-count":86,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,8,1]],"date-time":"2017-08-01T00:00:00Z","timestamp":1501545600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,8,1]],"date-time":"2017-08-01T00:00:00Z","timestamp":1501545600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"vor","delay-in-days":730,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100001003","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001003","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","resmedjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Respiratory Medicine"],"published-print":{"date-parts":[[2017,8]]},"DOI":"10.1016\/j.rmed.2017.05.017","type":"journal-article","created":{"date-parts":[[2017,5,31]],"date-time":"2017-05-31T12:48:52Z","timestamp":1496234932000},"page":"24-30","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":64,"special_numbering":"C","title":["Current approaches to the management of idiopathic pulmonary fibrosis"],"prefix":"10.1016","volume":"129","author":[{"given":"Ganesh","family":"Raghu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Richeldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.rmed.2017.05.017_bib1","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1164\/rccm.200709-1365OC","article-title":"Computed tomography findings in acute exacerbation of idiopathic pulmonary fibrosis","volume":"178","author":"Akira","year":"2008","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"9","key":"10.1016\/j.rmed.2017.05.017_bib2","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1136\/thoraxjnl-2014-206583","article-title":"Palliative care for patients with advanced fibrotic lung disease: a randomised controlled phase II and feasibility trial of a community case conference intervention","volume":"70","author":"Bajwah","year":"2015","journal-title":"Thorax"},{"issue":"6","key":"10.1016\/j.rmed.2017.05.017_bib3","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/S2213-2600(16)30044-3","article-title":"Safety and tolerability of acetylcysteine and pirfenidone combination therapy in idiopathic pulmonary fibrosis: a randomised, double-blind, placebo-controlled, phase 2 trial","volume":"4","author":"Behr","year":"2016","journal-title":"Lancet Respir. Med."},{"issue":"1","key":"10.1016\/j.rmed.2017.05.017_bib4","doi-asserted-by":"crossref","first-page":"e3","DOI":"10.1016\/S2213-2600(16)30418-0","article-title":"N-acetylcysteine for idiopathic pulmonary fibrosis: the door is still open-Authors' reply","volume":"5","author":"Behr","year":"2017","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.rmed.2017.05.017_bib5","series-title":"OFEV\u2122 (Nintedanib) Prescribing Information","author":"Boehringer Ingelheim Pharmaceuticals, Inc","year":"2016"},{"key":"10.1016\/j.rmed.2017.05.017_bib6","series-title":"Ofev (Nintedanib) Summary of Product Characteristics","author":"Boehringer Ingelheim International GmbH","year":"2016"},{"key":"10.1016\/j.rmed.2017.05.017_bib7","first-page":"6407","article-title":"Idiopathic pulmonary fibrosis: current treatment options and critical appraisal of nintedanib","volume":"9","author":"Bonella","year":"2015","journal-title":"Drug Des. Devel Ther."},{"issue":"2","key":"10.1016\/j.rmed.2017.05.017_bib8","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1183\/13993003.01204-2015","article-title":"European IPF Patient Charter: unmet needs and a call to action for healthcare policymakers","volume":"47","author":"Bonella","year":"2016","journal-title":"Eur. Respir. J."},{"issue":"3","key":"10.1016\/j.rmed.2017.05.017_bib9","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1177\/039463201202500314","article-title":"Pulmonary hypertension in idiopathic pulmonary fibrosis: prevalence and clinical progress","volume":"25","author":"Castria","year":"2012","journal-title":"Int. J. Immunopathol. Pharmacol."},{"issue":"7","key":"10.1016\/j.rmed.2017.05.017_bib10","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1164\/rccm.200703-463PP","article-title":"Idiopathic pulmonary fibrosis clinical research network investigators. Acute exacerbations of idiopathic pulmonary fibrosis","volume":"176","author":"Collard","year":"2007","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.rmed.2017.05.017_bib11","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/1465-9921-14-73","article-title":"IPFnet investigators. Suspected acute exacerbation of idiopathic pulmonary fibrosis as an outcome measure in clinical trials","volume":"14","author":"Collard","year":"2013","journal-title":"Respir. Res."},{"issue":"3","key":"10.1016\/j.rmed.2017.05.017_bib12","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1164\/rccm.201604-0801CI","article-title":"Acute exacerbation of idiopathic pulmonary fibrosis: an international working group report","volume":"194","author":"Collard","year":"2016","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.rmed.2017.05.017_bib13","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1186\/s12931-015-0276-5","article-title":"Safety, tolerability and appropriate use of nintedanib in idiopathic pulmonary fibrosis","volume":"16","author":"Corte","year":"2015","journal-title":"Respir. Res."},{"issue":"2","key":"10.1016\/j.rmed.2017.05.017_bib14","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1164\/rccm.201503-0562OC","article-title":"Efficacy of nintedanib in idiopathic pulmonary fibrosis across prespecified subgroups in INPULSIS","volume":"193","author":"Costabel","year":"2016","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"128","key":"10.1016\/j.rmed.2017.05.017_bib15","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1183\/09059180.00000813","article-title":"The impact of emphysema in pulmonary fibrosis","volume":"22","author":"Cottin","year":"2013","journal-title":"Eur. Respir. Rev."},{"issue":"Suppl 60","key":"10.1016\/j.rmed.2017.05.017_bib16","first-page":"OA4960","article-title":"Long-term treatment with nintedanib in patients with IPF: an update from INPULSIS\u00ae-ON","volume":"48","author":"Crestani","year":"2016","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.rmed.2017.05.017_bib17","first-page":"CD006322","article-title":"Pulmonary rehabilitation for interstitial lung disease","volume":"10","author":"Dowman","year":"2014","journal-title":"Cochrane Database Syst. Rev."},{"issue":"5","key":"10.1016\/j.rmed.2017.05.017_bib18","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1111\/jan.12587","article-title":"Perceptions, experiences and needs of patients with idiopathic pulmonary fibrosis","volume":"71","author":"Duck","year":"2015","journal-title":"J.\u00a0Adv. Nurs."},{"key":"10.1016\/j.rmed.2017.05.017_bib19","series-title":"The Voice of the Patient. Idiopathic Pulmonary Fibrosis","author":"Food and Drug Administration","year":"2015"},{"issue":"2","key":"10.1016\/j.rmed.2017.05.017_bib20","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1164\/rccm.201512-2393OC","article-title":"Accuracy and reliability of internet resources for information on idiopathic pulmonary fibrosis","volume":"194","author":"Fisher","year":"2016","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"1","key":"10.1016\/j.rmed.2017.05.017_bib21","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.jtcvs.2013.06.039","article-title":"Invasive mechanical ventilation in patients with fibrosing interstitial pneumonia","volume":"147","author":"Gaudry","year":"2014","journal-title":"J.\u00a0Thorac. Cardiovasc Surg."},{"issue":"12","key":"10.1016\/j.rmed.2017.05.017_bib22","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.4187\/respcare.03180","article-title":"Physical activity and quality of life improvements of patients with idiopathic pulmonary fibrosis completing a pulmonary rehabilitation program","volume":"59","author":"Gaunaurd","year":"2014","journal-title":"Respir. Care"},{"key":"10.1016\/j.rmed.2017.05.017_bib23","series-title":"ESBRIET\u00ae (Pirfenidone) Prescribing Information","author":"Genentech USA, Inc","year":"2015"},{"key":"10.1016\/j.rmed.2017.05.017_bib24","series-title":"Letairis (Ambrisentan) Prescribing Information","author":"Gilead Sciences, Inc","year":"2015"},{"issue":"2","key":"10.1016\/j.rmed.2017.05.017_bib25","doi-asserted-by":"crossref","first-page":"112","DOI":"10.2174\/1573398X113099990010","article-title":"Idiopathic pulmonary fibrosis: an EU patient perspective survey","volume":"9","author":"Giot","year":"2013","journal-title":"Curr. Respir. Med. Rev."},{"key":"10.1016\/j.rmed.2017.05.017_bib26","series-title":"Volibris (Ambrisentan) Summary of Product Characteristics","author":"Glaxo Group Ltd","year":"2016"},{"issue":"2","key":"10.1016\/j.rmed.2017.05.017_bib27","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1177\/1479972315571925","article-title":"Be honest and help me prepare for the future: what people with interstitial lung disease want from education in pulmonary rehabilitation","volume":"12","author":"Holland","year":"2015","journal-title":"Chron. Respir. Dis."},{"issue":"22","key":"10.1016\/j.rmed.2017.05.017_bib28","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1401739","article-title":"Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis","volume":"370","author":"Martinez","year":"2014","journal-title":"N.\u00a0Engl. J. Med."},{"issue":"4","key":"10.1016\/j.rmed.2017.05.017_bib29","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1183\/09031936.00122213","article-title":"Acute exacerbation of idiopathic pulmonary fibrosis associated with air pollution exposure","volume":"43","author":"Johannson","year":"2014","journal-title":"Eur. Respir. J."},{"issue":"1","key":"10.1016\/j.rmed.2017.05.017_bib30","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1164\/rccm.200705-732OC","article-title":"BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis","volume":"177","author":"King","year":"2008","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"1","key":"10.1016\/j.rmed.2017.05.017_bib31","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1164\/rccm.201011-1874OC","article-title":"BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis","volume":"184","author":"King","year":"2011","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"22","key":"10.1016\/j.rmed.2017.05.017_bib32","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1056\/NEJMoa1402582","article-title":"ASCEND Study Group. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis","volume":"370","author":"King","year":"2014","journal-title":"N.\u00a0Engl. J. Med."},{"issue":"1","key":"10.1016\/j.rmed.2017.05.017_bib33","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/S2213-2600(16)30222-3","article-title":"Idiopathic pulmonary fibrosis: effects and optimal management of comorbidities","volume":"5","author":"King","year":"2017","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.rmed.2017.05.017_bib34","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1186\/1471-2466-14-139","article-title":"Lung transplantation in idiopathic pulmonary fibrosis: a systematic review of the literature","volume":"14","author":"Kistler","year":"2014","journal-title":"BMC Pulm. Med."},{"issue":"4","key":"10.1016\/j.rmed.2017.05.017_bib35","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1136\/thoraxjnl-2016-208710","article-title":"Nintedanib in patients with idiopathic pulmonary fibrosis and preserved lung volume","volume":"72","author":"Kolb","year":"2017","journal-title":"Thorax"},{"issue":"6","key":"10.1016\/j.rmed.2017.05.017_bib36","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.resinv.2015.04.005","article-title":"Risk factors for acute exacerbation of idiopathic pulmonary fibrosis - extended analysis of pirfenidone trial in Japan","volume":"53","author":"Kondoh","year":"2015","journal-title":"Respir. Investig."},{"issue":"3","key":"10.1016\/j.rmed.2017.05.017_bib37","doi-asserted-by":"crossref","first-page":"e0151425","DOI":"10.1371\/journal.pone.0151425","article-title":"Impact of comorbidities on mortality in patients with idiopathic pulmonary fibrosis","volume":"11","author":"Kreuter","year":"2016","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.rmed.2017.05.017_bib38","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/S2213-2600(16)00067-9","article-title":"Antacid therapy and disease outcomes in idiopathic pulmonary fibrosis: a pooled analysis","volume":"4","author":"Kreuter","year":"2016","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.rmed.2017.05.017_bib39","doi-asserted-by":"crossref","first-page":"e000105","DOI":"10.1136\/bmjresp-2015-000105","article-title":"Safety of pirfenidone in patients with idiopathic pulmonary fibrosis: integrated analysis of cumulative data from 5 clinical trials","volume":"3","author":"Lancaster","year":"2016","journal-title":"BMJ Open Resp. Res."},{"issue":"8","key":"10.1016\/j.rmed.2017.05.017_bib40","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1164\/rccm.200605-587ST","article-title":"ATS End-of-Life Care Task Force. An official American Thoracic Society clinical policy statement: palliative care for patients with respiratory diseases and critical illnesses","volume":"177","author":"Lanken","year":"2008","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"12","key":"10.1016\/j.rmed.2017.05.017_bib41","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1164\/rccm.201101-0138OC","article-title":"Gastroesophageal reflux therapy is associated with longer survival in patients with idiopathic pulmonary fibrosis","volume":"184","author":"Lee","year":"2011","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"2","key":"10.1016\/j.rmed.2017.05.017_bib42","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1183\/09031936.00050911","article-title":"Bronchoalveolar lavage pepsin in acute exacerbation of idiopathic pulmonary fibrosis","volume":"39","author":"Lee","year":"2012","journal-title":"Eur. Respir. J."},{"issue":"5","key":"10.1016\/j.rmed.2017.05.017_bib43","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/S2213-2600(13)70105-X","article-title":"IPFnet Investigators. Anti-acid treatment and disease progression in idiopathic pulmonary fibrosis: an analysis of data from three randomised controlled trials","volume":"1","author":"Lee","year":"2013","journal-title":"Lancet Respir. Med."},{"issue":"7","key":"10.1016\/j.rmed.2017.05.017_bib44","doi-asserted-by":"crossref","first-page":"331","DOI":"10.12968\/ijpn.2012.18.7.331","article-title":"Palliative and end-of-life care for patients with idiopathic pulmonary fibrosis: challenges and dilemmas","volume":"18","author":"Lewis","year":"2012","journal-title":"Int. J. Palliat. Nurs."},{"issue":"4","key":"10.1016\/j.rmed.2017.05.017_bib45","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.hrtlng.2009.08.005","article-title":"Impact of a disease-management program on symptom burden and health-related quality of life in patients with idiopathic pulmonary fibrosis and their care partners","volume":"39","author":"Lindell","year":"2010","journal-title":"Heart Lung"},{"issue":"2","key":"10.1016\/j.rmed.2017.05.017_bib46","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1378\/chest.14-1127","article-title":"Palliative care and location of death in decedents with idiopathic pulmonary fibrosis","volume":"147","author":"Lindell","year":"2015","journal-title":"Chest"},{"issue":"Suppl.\u00a059","key":"10.1016\/j.rmed.2017.05.017_bib47","first-page":"OA4499","article-title":"Effect of baseline FVC on lung function decline with nintedanib in patients with IPF","volume":"46","author":"Maher","year":"2015","journal-title":"Eur. Respir. J."},{"issue":"Suppl.60","key":"10.1016\/j.rmed.2017.05.017_bib48","first-page":"OA4959","article-title":"No effect of baseline diffusing capacity of lung for carbon monoxide on benefit of nintedanib","volume":"48","author":"Maher","year":"2016","journal-title":"Eur. Respir. J."},{"issue":"1","key":"10.1016\/j.rmed.2017.05.017_bib49","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S2213-2600(16)30326-5","article-title":"Effect of pirfenidone on mortality: pooled analyses and meta-analyses of clinical trials in idiopathic pulmonary fibrosis","volume":"5","author":"Nathan","year":"2017","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.rmed.2017.05.017_bib50","series-title":"Idiopathic pulmonary fibrosis in adults. Quality standard","author":"National Institute for Health and Care Excellence (NICE)","year":"2015"},{"issue":"5","key":"10.1016\/j.rmed.2017.05.017_bib51","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1183\/09031936.00152609","article-title":"A\u00a0simple assessment of dyspnoea as a prognostic indicator in idiopathic pulmonary fibrosis","volume":"36","author":"Nishiyama","year":"2010","journal-title":"Eur. Respir. J."},{"issue":"9779","key":"10.1016\/j.rmed.2017.05.017_bib52","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1016\/S0140-6736(11)60405-4","article-title":"CAPACITY Study Group. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials","volume":"377","author":"Noble","year":"2011","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.rmed.2017.05.017_bib53","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1183\/13993003.00026-2015","article-title":"Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials","volume":"47","author":"Noble","year":"2016","journal-title":"Eur. Respir. J."},{"issue":"12","key":"10.1016\/j.rmed.2017.05.017_bib54","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1164\/rccm.201505-1010OC","article-title":"IPFnet Investigators. TOLLIP, MUC5B, and the response to N-ccetylcysteine among individuals with idiopathic pulmonary fibrosis","volume":"192","author":"Oldham","year":"2015","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"5","key":"10.1016\/j.rmed.2017.05.017_bib55","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1183\/13993003.01566-2015","article-title":"The lived experience with idiopathic pulmonary fibrosis: a qualitative study","volume":"47","author":"Overgaard","year":"2016","journal-title":"Eur. Respir. J."},{"issue":"6","key":"10.1016\/j.rmed.2017.05.017_bib56","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1164\/rccm.2009-040GL","article-title":"ATS\/ERS\/JRS\/ALAT Committee on Idiopathic Pulmonary Fibrosis. An official ATS\/ERS\/JRS\/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management","volume":"183","author":"Raghu","year":"2011","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"9","key":"10.1016\/j.rmed.2017.05.017_bib57","doi-asserted-by":"crossref","first-page":"641","DOI":"10.7326\/0003-4819-158-9-201305070-00003","article-title":"ARTEMIS-IPF Investigators, Treatment of idiopathic pulmonary fibrosis with ambrisentan: a parallel, randomized trial","volume":"158","author":"Raghu","year":"2013","journal-title":"Ann. Intern Med."},{"issue":"6","key":"10.1016\/j.rmed.2017.05.017_bib58","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1183\/09031936.00104612","article-title":"MUSIC Study Group. Macitentan for the treatment of idiopathic pulmonary fibrosis: the randomised controlled MUSIC trial","volume":"42","author":"Raghu","year":"2013","journal-title":"Eur. Respir. J."},{"issue":"2","key":"10.1016\/j.rmed.2017.05.017_bib59","doi-asserted-by":"crossref","first-page":"e3","DOI":"10.1164\/rccm.201506-1063ST","volume":"192","author":"Raghu","year":"2015","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"4","key":"10.1016\/j.rmed.2017.05.017_bib60","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1183\/13993003.02316-2014","article-title":"Comorbidities in idiopathic pulmonary fibrosis patients: a systematic literature review","volume":"46","author":"Raghu","year":"2015","journal-title":"Eur. Respir. J."},{"issue":"1","key":"10.1016\/j.rmed.2017.05.017_bib61","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1183\/13993003.01653-2015","article-title":"Incidence and prevalence of idiopathic pulmonary fibrosis in US adults 18-64 years old","volume":"48","author":"Raghu","year":"2016","journal-title":"Eur. Respir. J."},{"issue":"9","key":"10.1016\/j.rmed.2017.05.017_bib62","doi-asserted-by":"crossref","first-page":"e46","DOI":"10.1016\/S2213-2600(16)30234-X","article-title":"Anti-acid treatment in patients with IPF: interpret results from post-hoc, subgroup, and exploratory analyses with great caution","volume":"4","author":"Raghu","year":"2016","journal-title":"Lancet Respir. Med."},{"issue":"1","key":"10.1016\/j.rmed.2017.05.017_bib63","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1164\/rccm.201602-0402OC","article-title":"Effect of nintedanib in subgroups of idiopathic pulmonary fibrosis by diagnostic criteria","volume":"195","author":"Raghu","year":"2017","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"1","key":"10.1016\/j.rmed.2017.05.017_bib64","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/S2213-2600(16)30327-7","article-title":"N-acetylcysteine for idiopathic pulmonary fibrosis: the door is still open","volume":"5","author":"Raghu","year":"2017","journal-title":"Lancet Respir. Med."},{"issue":"12","key":"10.1016\/j.rmed.2017.05.017_bib65","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1056\/NEJMoa1103690","article-title":"Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis","volume":"365","author":"Richeldi","year":"2011","journal-title":"N.\u00a0Engl. J. Med."},{"issue":"22","key":"10.1016\/j.rmed.2017.05.017_bib66","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1056\/NEJMoa1402584","article-title":"Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis","volume":"370","author":"Richeldi","year":"2014","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.rmed.2017.05.017_bib67","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.rmed.2016.02.001","article-title":"Nintedanib in patients with idiopathic pulmonary fibrosis: combined evidence from the TOMORROW and INPULSIS\u00ae trials","volume":"113","author":"Richeldi","year":"2016","journal-title":"Respir. Med."},{"key":"10.1016\/j.rmed.2017.05.017_bib68","series-title":"Esbriet (Pirfenidone) Summary of Product Characteristics","author":"Roche Registration Ltd","year":"2015"},{"key":"10.1016\/j.rmed.2017.05.017_bib69","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.rmed.2015.12.005","article-title":"The use of mechanical ventilation in patients with idiopathic pulmonary fibrosis in the United States: a nationwide retrospective cohort analysis","volume":"111","author":"Rush","year":"2016","journal-title":"Respir. Med."},{"issue":"1","key":"10.1016\/j.rmed.2017.05.017_bib70","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s12890-016-0171-y","article-title":"Qualitative European survey of patients with idiopathic pulmonary fibrosis: patients' perspectives of the disease and treatment","volume":"16","author":"Russell","year":"2016","journal-title":"BMC Pulm. Med."},{"issue":"6","key":"10.1016\/j.rmed.2017.05.017_bib71","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1111\/j.1440-1843.2011.01996.x","article-title":"Cough predicts prognosis in idiopathic pulmonary fibrosis","volume":"16","author":"Ryerson","year":"2011","journal-title":"Respirology"},{"issue":"4","key":"10.1016\/j.rmed.2017.05.017_bib72","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/j.jpainsymman.2011.04.026","article-title":"Dyspnea in idiopathic pulmonary fibrosis: a systematic review","volume":"43","author":"Ryerson","year":"2012","journal-title":"J.\u00a0Pain Symptom Manage"},{"issue":"3","key":"10.1016\/j.rmed.2017.05.017_bib73","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1111\/j.1440-1843.2011.02122.x","article-title":"Depression is a common and chronic comorbidity in patients with interstitial lung disease","volume":"17","author":"Ryerson","year":"2012","journal-title":"Respirology"},{"issue":"9","key":"10.1016\/j.rmed.2017.05.017_bib74","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1001\/jama.2015.1175","article-title":"Single- vs double-lung transplantation in patients with chronic obstructive pulmonary disease and idiopathic pulmonary fibrosis since the implementation of lung allocation based on medical need","volume":"313","author":"Schaffer","year":"2015","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.rmed.2017.05.017_bib75","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1183\/09031936.00159709","article-title":"Acute exacerbation of idiopathic pulmonary fibrosis: incidence, risk factors and outcome","volume":"37","author":"Song","year":"2011","journal-title":"Eur. Respir. J."},{"issue":"1","key":"10.1016\/j.rmed.2017.05.017_bib76","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/2049-6958-7-42","article-title":"Idiopathic pulmonary fibrosis: diagnostic pitfalls and therapeutic challenges","volume":"7","author":"Spagnolo","year":"2012","journal-title":"Multidiscip. Respir. Med."},{"issue":"7","key":"10.1016\/j.rmed.2017.05.017_bib77","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1136\/thx.2004.035220","article-title":"Health-related quality of life in patients with idiopathic pulmonary fibrosis: a systematic review","volume":"60","author":"Swigris","year":"2005","journal-title":"Thorax"},{"issue":"6","key":"10.1016\/j.rmed.2017.05.017_bib78","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1007\/s00408-015-9794-7","article-title":"Ten-year survival in patients with idiopathic pulmonary fibrosis after lung transplantation","volume":"193","author":"Ten Klooster","year":"2015","journal-title":"Lung"},{"issue":"11","key":"10.1016\/j.rmed.2017.05.017_bib79","doi-asserted-by":"crossref","first-page":"767","DOI":"10.7326\/0003-4819-151-11-200912010-00004","article-title":"Survival after bilateral versus single-lung transplantation for idiopathic pulmonary fibrosis","volume":"151","author":"Thabut","year":"2009","journal-title":"Ann. Intern Med."},{"issue":"5","key":"10.1016\/j.rmed.2017.05.017_bib80","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1159\/000367899","article-title":"Exercise training-based pulmonary rehabilitation program is clinically beneficial for idiopathic pulmonary fibrosis","volume":"88","author":"Vainshelboim","year":"2014","journal-title":"Respiration"},{"issue":"3","key":"10.1016\/j.rmed.2017.05.017_bib81","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1007\/s00408-015-9703-0","article-title":"Long-term effects of a 12-week exercise training program on clinical outcomes in idiopathic pulmonary fibrosis","volume":"193","author":"Vainshelboim","year":"2015","journal-title":"Lung"},{"issue":"4","key":"10.1016\/j.rmed.2017.05.017_bib82","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/j.jcrc.2014.03.019","article-title":"Noninvasive ventilation in the event of acute respiratory failure in patients with idiopathic pulmonary fibrosis","volume":"29","author":"Vianello","year":"2014","journal-title":"J.\u00a0Crit. Care"},{"issue":"1","key":"10.1016\/j.rmed.2017.05.017_bib83","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.healun.2014.06.014","article-title":"A\u00a0consensus document for the selection of lung transplant candidates: 2014\u2013an update from the pulmonary transplantation council of the international society for heart and lung transplantation","volume":"34","author":"Weill","year":"2015","journal-title":"J.\u00a0Heart Lung Transpl."},{"issue":"6","key":"10.1016\/j.rmed.2017.05.017_bib84","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/S2213-2600(16)30085-6","article-title":"Acetylcysteine in IPF: the knockout blow?","volume":"4","author":"Wijsenbeek","year":"2016","journal-title":"Lancet Respir. Med."},{"issue":"5","key":"10.1016\/j.rmed.2017.05.017_bib85","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1007\/s00408-016-9912-1","article-title":"First data on efficacy and safety of nintedanib in patients with idiopathic pulmonary fibrosis and forced vital capacity of \u226450 % of predicted value","volume":"194","author":"Wuyts","year":"2016","journal-title":"Lung"},{"issue":"10","key":"10.1016\/j.rmed.2017.05.017_bib86","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1016\/j.healun.2015.08.014","article-title":"The registry of the International Society for Heart and Lung Transplantation: thirty-second official adult lung and heart-lung transplantation report\u20132015; focus theme: early graft failure","volume":"34","author":"Yusen","year":"2015","journal-title":"J.\u00a0Heart Lung Transpl."}],"container-title":["Respiratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0954611117301592?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0954611117301592?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T11:36:31Z","timestamp":1760614591000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0954611117301592"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8]]},"references-count":86,"alternative-id":["S0954611117301592"],"URL":"https:\/\/doi.org\/10.1016\/j.rmed.2017.05.017","relation":{},"ISSN":["0954-6111"],"issn-type":[{"value":"0954-6111","type":"print"}],"subject":[],"published":{"date-parts":[[2017,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Current approaches to the management of idiopathic pulmonary fibrosis","name":"articletitle","label":"Article Title"},{"value":"Respiratory Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rmed.2017.05.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}